Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


Preimplantation Genetic Diagnosis: The Who, the What, the Why and the How


 

Stem cell therapy for autism gets clinical trial go-ahead

28 August 2012

By Nishat Hyder

Appeared in BioNews 670

Stem cells harvested from patients' own umbilical cord blood are to be trialled in the USA as treatment for children with autism.

Researchers at the Sutter Neuroscience Institute in Sacramento, California, will conduct the first trial of its kind to be approved by the US regulator, the Food and Drug Administration.

Despite very few trials anywhere else in the world, stem cells treatments are openly marketed as therapies for autism in many countries. Dr Michael Chez, director of pediatric neurology at Sutter Medical Centre, who will be the study's principal investigator, told Nature Medicine's blog that the trial is 'important because many people are going to foreign countries and spending a lot of money on therapy that may not be valid'.

However, said Dr Chez, there is 'evidence to suggest that certain children with autism have dysfunctional immune systems that may be damaging or delaying the development of the nervous system'.

'Cord blood stem cells may offer ways to modulate or repair the immune systems of these patients', Dr Chez continued. Stem cells may also 'improve language and some behaviour in children who have no obvious reason to have become autistic'.

The trial will involve thirty children between the ages of two and seven where any identifiable cause for autism, such as a genetic condition or brain injury, remains elusive. Half of the trial group will be injected with the stem cells, the other half will receive placebo injections.

Both groups will be monitored for a period of six months, before switching to the opposite arm. The trial will be 'blind'; for the duration neither participants nor clinicians will know which arm of the trial they are on, to prevent biased results.

'Parents want so desperately to see a response, and therapists want to see a response, if you don’t have an appropriately blinded control study, you get an elevation of observation of response', Dr Chez told Bloomberg. 'That's true for any disease that has no cure, but more so with something subjective like autism'.

Clinicians will monitor patients' language and behaviour to assess whether any therapeutic benefit has occurred. Even if the trial is unsuccessful researchers expect it to provide valuable insight into the nature of autism spectrum disorders.

Some researchers are less than optimistic about the trial's outcome, however. Dr James Carroll, a paediatric neurologist at the Georgia Health Sciences University in the USA, has been running a clinical trial using stem cell therapy in patients with cerebral palsy for two years. 'So far we have not seen any kind of miraculous recovery in our cerebral palsy patients', he told the Nature Medicine blog, 'I would be delighted if that changes'.

Dr Ricardo Dolmetsch, a neurobiologist and autism researcher at Stanford University told Bloomberg: 'I commend them for having the guts to actually do [the trial], given that there are all kinds of people out there trying to sell [stem cell therapies]'. However he added that he did not think the trial would be 'big enough to provide an answer'.

According to the Centres for Disease Control and Prevention in the USA, one in 88 children in America is affected by an autism spectrum disorder. The results of a recent trial in China using donated cord blood stem cells are yet to be published, and researchers in Mexico are still in the early stages of a trial using stem cells harvested from participants' own fat tissue.

SOURCES & REFERENCES
Cord Blood Registry (press release) | 21 August 2012
 
Bloomberg | 21 August 2012
 
Spoonful of Medicine (Nature Medicine news blog) | 21 August 2012
 
Fox 13 News | 22 August 2012
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

10 April 2017 - by Dr Lucy Freem 
Children with autism spectrum disorder who received infusions of their own stem cells from banked umbilical cord blood as part of a clinical trial have no apparent lasting adverse effects after one year...
10 August 2015 - by Dr Nicola Davis 
A Canadian study has found that as many as ten percent of cerebral palsy cases have a genetic cause...
03 June 2013 - by Nishat Hyder 
The Italian Senate has approved an 18-month, €3 million clinical trial of a controversial stem cell-based therapy. The vote, on 22 May 2013, will also allow a hospital to continue to treat twelve patients already undergoing the contested treatment...
21 January 2013 - by Dr Victoria Burchell 
Rare genetic variants may have a significant impact on a person's risk of developing autism, research suggests...
17 September 2012 - by Dr Victoria Burchell 
A genetic test capable of predicting a person's risk of Autism Spectrum Disorders (ASDs), with an accuracy greater than 70 percent, has been developed by researchers...

13 August 2012 - by Dr Tamara Hirsch 
Scientists have identified a sub-type of stem cell responsible for neuron development within the cerebral cortex associated with higher level brain function...
16 April 2012 - by James Brooks 
Genetic mutations that occur spontaneously in sperm and egg cells may increase a child's risk of autism, say scientists...
26 March 2012 - by Dr Rosie Gilchrist 
Faulty genetic mechanisms particularly active in early life may lead to people developing autism, research suggests...
13 June 2011 - by Dr Lux Fatimathas 
American researchers have linked hundreds of spontaneous genetic mutations to the group of psychological syndromes called autism spectrum disorders (ASDs)...
31 May 2011 - by Mehmet Fidanboylu 
Gene activity in two brain regions is different in autism, scientists say. A US study found activity patterns were similar in the frontal and temporal lobes of people with autism, despite the lobes having different functions...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Richard Anderson

Dr Sue Avery

Dr Elizabeth Garner

Professor Allan Pacey

Dr Anna Smajdor

Dr Andy Greenfield

Philippa Taylor

Dr César Palacios-González

Fiona Fox

Sarah Norcross

EARLY BIRD DISCOUNT
if you book now


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation